Article
Pediatrics
Jiacheng Li, Xizhou An, Ximing Xu, Li Xiao, Yang Wang, Yao Zhu, Lan Huang, Kainan Zhang, Xinyuan Yao, Weijia Yi, Jiebin Qin, Jie Yu
Summary: This study aimed to identify risk indicators for early recurrence of primary warm-antibody autoimmune hemolytic anemia (w-AIHA) in children and construct an effective recurrence risk assessment model. The results showed that blood type O, low mean corpuscular hemoglobin concentration (MCHC), and high reticulocyte count (Ret) were risk indicators for early recurrence of pediatric primary w-AIHA.
FRONTIERS IN PEDIATRICS
(2022)
Article
Pediatrics
Anthie Damianaki, Marianna Tzanoudaki, Maria Kanariou, Emmanouil Liatsis, Alexandros Panos, Alexandra Soldatou, Lydia Kossiva
Summary: This is a case of a 3-year-old boy with severe and refractory warm antibody autoimmune hemolytic anemia. Despite B-cell recovery, the patient continued to have hypogammaglobulinemia 20 months after receiving rituximab therapy.
Article
Medicine, General & Internal
Zhuxin Zhang, Qinglin Hu, Chen Yang, Miao Chen, Bing Han
Summary: This study aimed to investigate the fine structure of T31M LCTIR latex particles and their role in cell fusion. The results showed that T31M LCTIR latex particles could stably exist on the surface of oocytes and form aggregated structures. The super-resolution microscopy images of cell fusion provided a deeper understanding of the process. These findings contribute to further research on the mechanism and function of stimulated T31M LCTIR latex particles.
ANNALS OF MEDICINE
(2023)
Review
Hematology
Wilma Barcellini, Bruno Fattizzo
Summary: Warm autoimmune hemolytic anemia is a disease caused by increased destruction of red blood cells by IgG autoantibodies, with complex pathogenic mechanisms and unpredictable prognosis. Treatment options include steroids, splenectomy, immunosuppressants, and rituximab, but challenges exist in choosing and managing these therapies.
Article
Hematology
Iara B. Rabelo, Akemi K. Chiba, Elyse Moritz, Paulo D'Amora, Ismael Dale C. G. Silva, Celso A. Rodrigues, Melca M. O. Barros, Jose O. Bordin
Summary: This study analyzed the metabolomic profile of patients with autoimmune hemolytic anemia (AIHA) and found changes in metabolites related to disease activity and hemolysis intensity. The PC ae 34:3 / PC ae 40:2 ratio was identified as a predictor of relapse. Increased sphingomyelin, ADMA, PC, and polyamines may interfere with autoantigen and autoimmune recognition mechanisms in AIHA.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Pathology
Jeremy W. Jacobs, Thomas C. Binns, Elizabeth Abels, Juan J. Silva Campos, Ragaa Elkabbani, Anna Kress, Nataliya Sostin, Christopher A. Tormey
Summary: In this study, 3 cases of red blood cell (RBC) autoantibodies with unusual apparent antigenic specificity were described, and the testing methodology and implications of these findings were discussed. All immunohematologic testing was performed using standardized and validated methods and reagents. These 3 cases complement the minimal literature regarding warm autoantibodies with unusual antigenic specificity and their potential to mediate clinically significant hemolysis.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2023)
Review
Medicine, General & Internal
Stinne Tranekaer, Dennis Lund Hansen, Henrik Frederiksen
Summary: This study summarized the clinical characteristics of patients with warm autoimmune haemolytic anaemia, revealing a higher proportion of female patients and a significant number of secondary cases, particularly those associated with systemic lupus erythematosus.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Immunology
Shasha Zhang, Jing Huang, Jianwei Dong, Zhuo Li, Mengyao Sun, Yujiao Sun, Bing Chen
Summary: This study observed and analyzed the efficacy and safety of rituximab (RTX) treatment for primary membranous nephropathy (PMN) in Chinese population, and found that RTX can effectively induce and maintain remission of PMN and stabilize renal function, and it is recommended as the first choice of treatment for PMN.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Zeinab Aryanian, Kamran Balighi, Maryam Daneshpazhooh, Emad Karamshahi, Parvaneh Hatami, Azadeh Goodarzi, Mahroo Tajalli, Terrence M. Vance
Summary: The study compared the side effect profiles of rituximab in two treatment strategies for pemphigus patients, and found that early use of rituximab is beneficial for certain patients, especially those with mucocutaneous phenotype, pulmonary comorbidity, or smoking history.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Surgery
Ajay Bhandarwar, Jaini Gala, Eham Arora, Raj Gajbhiye, Gagandeep Talwar, Saurabh Gandhi, Amol Wagh, Chintan Patel
Summary: Endoscopic parathyroidectomy is a safe and feasible surgical procedure when combined with pre-operative imaging and intra-operative parathyroid hormone monitoring. Focused exploration is the current standard, wherein endoscopic surgery can be an important tool to improve outcomes for patients with primary hyperparathyroidism.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2021)
Review
Hematology
Maria Gabelli, Christine Ademokun, Nichola Cooper, Persis I. Amrolia
Summary: Post-HSCT AIHA is a rare and difficult-to-treat complication with high mortality rate, often requiring steroids and rituximab as main therapeutic options with relatively low response rates. Prospective studies are needed to guide clinicians in managing these complex patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Immunology
Sarah Stabler, Jonathan Giovannelli, David Launay, Angelique Cotteau-Leroy, Marion Heusele, Guillaume Lefevre, Louis Terriou, Marc Lambert, Sylvain Dubucquoi, Eric Hachulla, Vincent Sobanski
Summary: This study found that the incidence of serious infectious events (SIEs) in patients with autoimmune disease (AID) treated with RTX was 17.3 and 11.3 per 100 person-years at 1 and 2 years, respectively. The main SIEs observed were pneumonia and bacteremia, and identified risk factors included age, history of diabetes, history of cancer, concomitant steroid treatment, and low CD4 lymphocyte count at RTX initiation.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Medicine, General & Internal
Maria Arguello Marina, Montserrat Lopez Rubio, Lucia Castilla Garcia
Summary: Autoimmune haemolytic anaemias (AIHA) are acquired haematological disorders caused by autoantibodies against erythrocyte antigens, and they can be classified into primary and secondary according to the aetiology, and into warm antibody AIHA (w-AIHA) and cold antibody AIHA (c-AIHA) based on the type of antibody and reaction temperature. Glucocorticoid therapy is the main treatment for w-AIHA, and recent studies have shown that the early addition of rituximab has good results. Primary c-AIHA is mainly treated with rituximab, alone or in combination with chemotherapy. New drugs such as Syk inhibitors, anti-FcRn Ig, and complement inhibitors are being developed and will expand the therapeutic arsenal, especially for refractory or relapsed cases.
Article
Medicine, General & Internal
Natalia Mena-Vazquez, Rocio Redondo-Rodriguez, Marta Rojas-Gimenez, Carmen Maria Romero-Barco, Sara Manrique-Arija, Rafaela Ortega-Castro, Ana Hidalgo Conde, Rocio Arnedo Diez de los Rios, Eva Cabrera Cesar, Francisco Espildora, Maria Carmen Aguilar-Hurtado, Isabel Anon-Onate, Lorena Perez-Albaladejo, Manuel Abarca-Costalago, Inmaculada Urena-Garnica, Maria Luisa Velloso-Feijoo, Maria Victoria Irigoyen-Oyarzabal, Antonio Fernandez-Nebro
Summary: The study showed that in patients with connective tissue disease associated interstitial lung disease treated with rituximab, over half of the patients showed improvement or stabilization of the disease at the end of follow-up. Early treatment and combination with mycophenolate could reduce the risk of ILD progression.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Juri Alessandro Giannotta, Bruno Fattizzo, Francesca Cavallaro, Wilma Barcellini
Summary: This review provides an overview of the frequency and types of infectious complications in patients with autoimmune hemolytic anemia (AIHA), as well as the risks associated with various treatments. It also discusses infectious complications in AIHA secondary to other diseases and viral and bacterial reactivations during immune suppressive therapies, along with suggested screening and prophylactic strategies.
JOURNAL OF CLINICAL MEDICINE
(2021)
Letter
Rheumatology
Roman Praliaud, Helene Greigert, Maxime Samson, Marianne Zeller, Mathieu Boulin, Philip Bielefeld, Andre Ramon, Yves Cottin, Bernard Bonnotte
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Michele Iudici, Christian Pagnoux, Delphine S. Courvoisier, Pascal Cohen, Mohamed Hamidou, Achille Aouba, Francois Lifermann, Marc Ruivard, Olivier Aumaitre, Bernard Bonnotte, Francois Maurier, Olivier Decaux, Eric Hachulla, Alexandre Karras, Chahera Khouatra, Noemie Jourde-Chiche, Jean-Francois Viallard, Claire Blanchard-Delaunay, Pascal Godmer, Alain Le Quellec, Thomas Quemeneur, Claire de Moreuil, Alexis Regent, Benjamin Terrier, Luc Mouthon, Loic Guillevin, Xavier Puechal
Summary: This study describes the characteristics and long-term outcomes of patients with GPA from the French Vasculitis Study Group database. It found that PR3-ANCA positivity was associated with increased probability of relapse and prolonged survival.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2021)
Article
Rheumatology
Hubert de Boysson, Olivier Espitia, Maxime Samson, Nathalie Tieulie, Claude Bachmeyer, Thomas Moulinet, Anael Dumont, Samuel Deshayes, Bernard Bonnotte, Christian Agard, Achille Aouba
Summary: This case study describes characteristics and outcomes of patients with giant cell arteritis (GCA)-related aortic dissection, showing a higher likelihood of aortic dissection in patients with prior large-vessel vasculitis. Surgery remains the most significant predictive factor for survival.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2021)
Editorial Material
Medicine, General & Internal
Anne-Claire Billet, Olivier Chevallier, Maxime Samson, Jean-Michel Petit, Bernard Bonnotte, Sylvain Audia
AMERICAN JOURNAL OF MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Celine Lairet, Helene Greigert, Thibaut Pommier, Thibault Leclercq, Maud Maza, Adrien Artus, Thibaud Genet, Maxime Samson, Laurent Fauchier, Marianne Zeller, Alexandre Cochet, Bernard Bonnotte, Yves Cottin
Summary: This prospective study introduces the concept of AMAF in patients with acute myocarditis, similar to the IPAF in interstitial pneumonia. Patients with AMAF had less myocardial damage in the acute phase and showed more favorable outcomes at 1-year follow-up. More research is needed to understand the clinical significance and long-term impact of this new concept.
Article
Rheumatology
Michele Iudici, Christian Pagnoux, Delphine S. Courvoisier, Pascal Cohen, Antoine Neel, Achille Aouba, Francois Lifermann, Marc Ruivard, Olivier Aumaitre, Bernard Bonnotte, Francois Maurier, Thomas Le Gallou, Eric Hachulla, Alexandre Karras, Chahera Khouatra, Noemie Jourde-Chiche, Jean-Francois Viallard, Claire Blanchard-Delaunay, Pascal Godmer, Alain Le Quellec, Thomas Quemeneur, Claire de Moreuil, Alexis Regent, Benjamin Terrier, Luc Mouthon, Loic Guillevin, Xavier Puechal
Summary: Patients with localized granulomatosis with polyangiitis (L-GPA) present with different clinical features compared to systemic GPA (S-GPA), with younger age, less frequent saddle nose deformity or subglottic stenosis, and lower PR3-ANCA positivity. Treatment strategies also vary, with less frequent use of CYC and more frequent use of a combination of MTX and glucocorticoids in L-GPA patients. Despite similar relapse risks between L-GPA and S-GPA, L-GPA patients have higher overall survival rates and more frequent relapses in the ENT and lung regions.
Article
Rheumatology
Alessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna, Vincent Cottin, Franco Franceschini, Stefano Del Giacco, Franco Schiavon, Thomas Neumann, Giuseppe Lopalco, Pavel Novikov, Chiara Baldini, Carlo Lombardi, Alvise Berti, Federico Alberici, Marco Folci, Simone Negrini, Renato Alberto Sinico, Luca Quartuccio, Claudio Lunardi, Paola Parronchi, Frank Moosig, Georgina Espigol-Frigole, Jan Schroeder, Anna Luise Kernder, Sara Monti, Ettore Silvagni, Claudia Crimi, Francesco Cinetto, Paolo Fraticelli, Dario Roccatello, Angelo Vacca, Aladdin J. Mohammad, Bernhard Hellmich, Maxime Samson, Elena Bargagli, Jan Willem Cohen Tervaert, Camillo Ribi, Davide Fiori, Federica Bello, Filippo Fagni, Luca Moroni, Giuseppe Alvise Ramirez, Mouhamad Nasser, Chiara Marvisi, Paola Toniati, Davide Firinu, Roberto Padoan, Allyson Egan, Benjamin Seeliger, Florenzo Iannone, Carlo Salvarani, David Jayne, Domenico Prisco, Augusto Vaglio, Giacomo Emmi
Summary: Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks proved effective in treating EGPA, with no significant difference between the two doses. Complete response rates reached 30.4% at 12 months and 35.7% at 24 months, with some patients experiencing exacerbations in asthma and ENT.
ARTHRITIS & RHEUMATOLOGY
(2022)
Letter
Hematology
Guillaume Moulis, Johanne Germain, Manuela Rueter, Margaux Lafaurie, Myriam Aroichane, Thibault Comont, Matthieu Mahevas, Jean-Francois Viallard, Stephane Cheze, Mikael Ebbo, Sylvain Audia, Soraya Leclerc-Teffahi, Agnes Sommet, Odile Beyne-Rauzy, Marc Michel, Bertrand Godeau, Maryse Lapeyre-Mestre
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Arthur Mageau, Louis Terriou, Mikael Ebbo, Odile Souchaud-Debouverie, Corentin Orvain, Julie Graveleau, Jean-Christophe Lega, Marc Ruivard, Jean-Francois Viallard, Stephane Cheze, Antoine Dossier, Bernard Bonnotte, Antoinette Perlat, Delphine Gobert, Nathalie Costedoat-Chalumeau, Pierre-Yves Jeandel, Amandine Dernoncourt, Marc Michel, Bertrand Godeau, Thibault Comont
Summary: Although the use of splenectomy has declined in recent years, it remains an effective treatment option for adult primary ITP patients who do not respond to TPO-RAs and rituximab. Some patients may experience relapse after splenectomy, but re-challenging with TPO-RAs can result in sustained response for some individuals.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Medicine, General & Internal
C. Mettler, C. A. Durel, P. Guilpain, B. Bonnotte, F. Cohen-Aubart, M. Hamidou, J. C. Lega, V Le Guern, F. Lifermann, V Poindron, G. Pugnet, A. Servettaz, X. Puechal, L. Guillevin, B. Terrier
Summary: This retrospective study examines the efficacy and safety of off-label use of biologics for refractory and/or relapsing granulomatosis with polyangiitis (GPA). The study suggests that the use of anti-TNF-alpha and abatacept shows efficacy in less than 50% of patients with refractory and/or relapsing GPA.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Rheumatology
Mickael Roussotte, Mathieu Gerfaud-Valentin, Arnaud Hot, Sylvain Audia, Bernard Bonnotte, Thomas Thibault, Herve Lobbes, Guillaume Le Guenno, Radjiv Goulabchand, Pascal Cathebras, Loig Varron, Jean-Francois Dufour, Alban Deroux, Caroline Compain, Antoine Baudet, Ludovic Karkowski, Laurent Perard, Mikael Ebbo, Jean-Christophe Lega, Pascal Seve
Summary: Patients with SLE-associated ITPCS displayed a high rate of hematological abnormalities, especially those who experienced major bleeding events, leading to higher morbidity. Management of thrombocytopenia was diverse and multiple treatment options seemed effective.
Review
Medicine, General & Internal
Helene Greigert, Andre Ramon, Georges Tarris, Laurent Martin, Bernard Bonnotte, Maxime Samson
Summary: In the presence of temporal arteritis, differential diagnoses should be considered as other vascular diseases, vasculitis or not, may affect the temporal artery. This review describes the different diseases that can affect the temporal artery, including vasculitis, infections, and drugs.
JOURNAL OF CLINICAL MEDICINE
(2022)
Editorial Material
Rheumatology
Maxime Samson, Helene Greigert, Andre Ramon, Bernard Bonnotte
Meeting Abstract
Oncology
Maroua Abdallahoui, Jerome Razanamahery, Agnes Fromont, Julien Haroche, Ahmed Idbaih, Guillaume Chabridon, Sylvain Audia, Bernard Bonnotte
PEDIATRIC BLOOD & CANCER
(2022)
Meeting Abstract
Oncology
Jerome Razanamahery, Maxime Samson, Julien Guy, Stephanie Francois, Jean-Francois Emile, Fleur Cohen-Aubart, Julien Haroche, Sylvain Audia, Bernard Bonnotte
PEDIATRIC BLOOD & CANCER
(2022)
